Drug Database · Clinicians

Irbesartan

Brands (62) Ibetan, Albestan, Aprovel…Show all

US brand (reference label): Avapro; not a Philippine-registered brand.

Angiotensin 2 Receptor Blocker (Angiotensin 2 Receptor Antagonists) US FDA class
Angiotensin II receptor blocker (ARB); Angiotensin II receptor antagonist; and others PH FDA category

Rx · Prescription drug113 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 7885b2a8-be4e-48ab-8113-4e6ab791eb98, version date August 24, 2026 (Avapro · Sanofi-Aventis U.S. LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Treatment of hypertension, to lower blood pressure.
  • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria.

(1.2) 1.1 Hypertension AVAPRO ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. AVAPRO may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients AVAPRO is indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day).

In this population, AVAPRO reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)].

Contraindications

4 CONTRAINDICATIONS AVAPRO is contraindicated in patients who are hypersensitive to any component of this product. Do not coadminister aliskiren with AVAPRO in patients with diabetes. Hypersensitivity to any component of this product. (4) Coadministration with aliskiren in patients with diabetes. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Indication Dose Hypertension (2.2)
  • 150 to 300 mg once daily Diabetic Nephropathy (2.3)
  • 300 mg once daily
2.1 General Considerations

2.1 General Considerations AVAPRO may be administered with other antihypertensive agents and with or without food.

2.2 Hypertension

2.2 Hypertension The recommended initial dose of AVAPRO is 150 mg once daily. The dosage can be increased to a maximum dose of 300 mg once daily as needed to control blood pressure [see Clinical Studies (14.1)].

2.3 Nephropathy in Type 2 Diabetic Patients

2.3 Nephropathy in Type 2 Diabetic Patients The recommended dose is 300 mg once daily [see Clinical Studies (14.2)].

2.4 Dose Adjustment in Volume and Salt-Depleted Patients

2.4 Dose Adjustment in Volume and Salt-Depleted Patients The recommended initial dose is 75 mg once daily in patients with depletion of intravascular volume or salt (e.g., patients treated vigorously with diuretics or on hemodialysis) [see Warnings and Precautions (5.2)].

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

2 DOSAGE AND ADMINISTRATION Indication Dose Hypertension ( 2.2 ) 150 to 300 mg once daily Diabetic Nephropathy ( 2.3 ) 300 mg once daily 2.1 General Considerations AVAPRO may be administered with other antihypertensive agents and with or without food.

2.3 Nephropathy in Type 2 Diabetic Patients The recommended dose is 300 mg once daily [see Clinical Studies (14.2) ] .

2.4 Dose Adjustment in Volume and Salt-Depleted Patients The recommended initial dose is 75 mg once daily in patients with depletion of intravascular volume or salt (e.g., patients treated vigorously with diuretics or on hemodialysis) [see Warnings and Precautions (5.2) ] .

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Irbesartan, in a study at a dose of up to 4.5 mg/kg/day, once daily, did not appear to lower blood pressure effectively in pediatric patients ages 6 to 16 years. AVAPRO has not been studied in pediatric patients less than 6 years old.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of 4925 subjects receiving AVAPRO in controlled clinical studies of hypertension, 911 (18.5%) were 65 years and over, while 150 (3.0%) were 75 years and over. No overall differences in effectiveness or safety were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. [See Clinical Pharmacology (12.3) and Clinical Studies (14.1).]

Dosage forms

Philippines

  • Film-coated tablet: 75 mg, 150 mg, 300 mg
  • Tablet: 75 mg, 150 mg, 300 mg

Registered products in the Philippines

113 products registered with the Food and Drug Administration (FDA) Philippines list Irbesartan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products113
Philippine FDA-registered products for Irbesartan
Package insert
AlbestanIrbesartan
150 mg Film-Coated TabletAlu-White PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Wecare Pharma Corp.Trader: Foramen Products Corporation
DRP-17027-01
Oct 28, 2029
AlbestanIrbesartan
150 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Euro-Health Care Exponents, Inc.Trader: Dr. Zen's Research, Inc.
DRP-7554-01
Sep 15, 2029
AprotanIrbesartan
150 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Standard Chem. & Pharm. Co., Ltd.Taiwan
Standard Chem & Pharm. Philippines, Inc.
DRP-10589
Oct 20, 2031
AprovelIrbesartan
150 mg Film-Coated TabletAlu/White Opaque PVC/PVDC blister pack x 14's (Box of 28's)
RxVAT-exempt
Sanofi Winthrop IndustrieFrance
Importer: Sanofi-Aventis Philippines, Inc.
DRP-5716
May 3, 2027
AprovelIrbesartan
300 mg Film-Coated TabletAlu/White Opaque PVC/PVDC blister pack x 14's (Box of 28's)
RxVAT-exempt
Sanofi Winthrop IndustrieFrance
Importer: Sanofi-Aventis Philippines, Inc.
DRP-5715
May 3, 2027
Arten 150Irbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's & 7's (Box of 10's & 28's)
RxVAT-exempt
Lek Pharmaceuticals d.dSlovenia
Emcure Pharma Philippines Inc.Importer: Sandoz Philippines Corporation
DRP-4386-02
Apr 26, 2028
Arten 300Irbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Lek Pharmaceuticals D.D.Slovenia
Emcure Pharma Philippines Inc.Importer: Sandoz Philippines Corporation
DRP-4387-01
Apr 26, 2028
ArvezarIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-13896
May 12, 2028
BelizarIrbesartan
150 mg Film-Coated TabletOpaque white PVC/PVDC - Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Amediqo Phils., Inc.Importer: One Dexcel Pharma Inc.
DRP-8517-01
Oct 24, 2029
BelizarIrbesartan
300 mg Film-Coated TabletOpaque white PVC/PVDC - Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Amediqo Phils., Inc.Importer: One Dexcel Pharma Inc.
DRP-8516-01
Oct 24, 2029
BezartanIrbesartan
150 mg Film-Coated TabletAlu/Opaque PVDC blister pack x 10's (box of 30's)
RxVAT-exempt
Duopharma Manufacturing (Bangi) Sdn. Bhd.Malaysia
Importer: DB (Philippines), Inc.
DR-XY49071
May 6, 2029
BezartanIrbesartan
300mg Film-Coated TabletAlu/Opaque PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Duopharma Manufacturing (Bangi) Sdn. Bhd.Malaysia
Importer: DB (Philippines), Inc.
DR-XY48815
Jul 18, 2028
Crovel 150Irbesartan
150mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-13323
Jan 26, 2028
Crovel 300Irbesartan
300mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-13324
Jan 26, 2028
IbertanIrbesartan
300 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-14537
Oct 4, 2028
IbetanIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mepro Pharmaceuticals Private LimitedIndia
Corbridge Group Phils., IncImporter: Medethix, Inc.
DRP-16216-01
Dec 17, 2031
IbetanIrbesartan
150 mg TabletAluminum/PVC/PE/PVDC Blister Pack x 14's (Box of 28's); Aluminum/PVC/PE/PVDC Blister Pack x 14's (Box of 98's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Corbridge Group Phils., Inc.Importer: I.E. Medica, Inc.
DRP-2658
Dec 23, 2028
IbetanIrbesartan
300 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Mepro Pharmaceuticals Private LimitedIndia
CORBRIDGE GROUP PHILS.,INC.Importer: MedEthix Inc.
DRP-16215-01
Dec 17, 2031
IbetanIrbesartan
300 mg TabletAluminum/PVC/PE/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Corbridge Group Phils., Inc.Importer: I.E. Medica, Inc.
DRP-2659
Dec 23, 2028
IdezarIrbesartan
150 mg Film-Coated TabletAluminum/White Opaque PVC-PVDC Blister Pack 14's (Box of 28's)
RxVAT-exempt
USV Private LimitedIndia
UNILAB, INC.
DR-XY40422
Dec 19, 2028
IdezarIrbesartan
300 mg Film-Coated TabletAluminum/White Opaque PVC-PVDC Blister Pack 14's (Box of 28's)
RxVAT-exempt
USV Private LimitedIndia
Unilab, Inc.
DR-XY40423
Dec 19, 2028
IrbecardIrbesartan
300 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Transcend Phils., Inc.
DRP-7633
Jan 28, 2030
IrbedenzIrbesartan
150 mg TabletAluminum/PVC/PE/PVDC Blister Pack x 14's (Box of 28's); Aluminum/PVC/PE/PVDC Blister Pack x 14's (Box of 98's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Importer: I.E. Medica, Inc.Trader: Meedpharma Medical Supplies & Equipment Distributor
DRP-2658-01
Dec 23, 2028
IrbedenzIrbesartan
300 mg TabletAluminum/PVC/PE/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Meedpharma Medical Supplies & Equipment DistributorImporter: I.E. Medica, Inc.
DRP-2659-01
Dec 23, 2028
IrbefarIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-12740
Sep 29, 2027
IrbefastIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17529
Jan 20, 2031
IrbefastIrbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17519
Jan 16, 2031
IrbegenIrbesartan
300 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Innogen Pharmaceuticals, Inc.
DR-XY39986
Sep 2, 2029
IrbemedIrbesartan
150 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY43874
Nov 11, 2029
Irbenov-150Irbesartan
150 mg Film-Coated TabletAlu/Clear PVC/PE/PVdC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Macleods Pharmaceuticals Limited (Unit II)India
Medinova Pharmaceutical, Inc.
DRP-14217
Jul 28, 2028
Irbenov-300Irbesartan
300mg Film Coated TabletAlu/Clear PVC/PE/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Macleods Pharmaceuticals Limited (Unit II)India
Medinova Pharmaceutical, Inc.
DRP-11904
May 18, 2027
IrbenoxIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's & 7's (Box of 10 & 28's)
RxVAT-exempt
Lek Pharmaceuticals D.D.Slovenia
Sandoz Philippines Corporation
DRP-4386
Apr 26, 2028
IrbenoxIrbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Lek Pharmaceuticals D.D.Slovenia
Importer: Sandoz Philippines Corporation
DRP-4387
Apr 26, 2028
Irbeq 150Irbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-11932
May 23, 2032
Irbeq 150Irbesartan
150mg TabletAlu/Alu blister pack x 10's (Box of 100's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-13521
Mar 3, 2028
Irbeq 300Irbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-11931
May 23, 2032
Irbeq 300Irbesartan
300mg TabletAlu/Alu blister pack x 10's (Box of 100's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-13520
Mar 3, 2028
Irbeschwartz 150Irbesartan
150 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Cooper Pharma LimitedIndia
Medcare PharmaceuticalsImporter: Ambica International Corporation
DRP-13010-04
Nov 17, 2027
IrbespeedIrbesartan
150 mg TabletFoil Strip x 4's (Box of 100's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Speed Med Pharmaceuticals Inc.
DRP-3839-06
May 16, 2031
IrbespeedIrbesartan
300 mg TabletFoil Strip x 4's (Box of 100's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Speed Med Pharmaceuticals
DRP-3871-05
May 16, 2031
IrbetanIrbesartan
150 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) (Box of 30's)
RxVAT-exempt
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc
DRP-16425
Mar 10, 2030
IrbetanIrbesartan
75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-16424
Mar 10, 2030
Irbetris-150Irbesartan
150 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-17361
Nov 20, 2030
Irbetris-300Irbesartan
300 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-17360
Nov 20, 2030
Irbevex 150Irbesartan
150 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Cooper Pharma LimitedIndia
VE Pharma Inc.Importer: Ambica International Corporation
DRP-13010-02
Nov 17, 2027
Irbevex 300Irbesartan
300 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Cooper Pharma LimitedIndia
VE Pharma Inc.Importer: Ambica International Corporation
DRP-13009-02
Nov 17, 2027
Irbexcel-150Irbesartan
150 mg Film-Coated TabletOpaque White PVC/PVDC - Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
One Dexcel Pharma Inc.
DRP-8517
Oct 24, 2029
IrbexlIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-6398
Oct 28, 2029
Irbexl-300Irbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-6399
Oct 28, 2029
Irbez 150Irbesartan
150 mg TabletAluminum foil (Silver) - PVC/PVDC (Amber brown) Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Unison Laboratories Co., Ltd.Thailand
JustRight Healthcare Inc.
DR-XY45098
Feb 19, 2032
Irbez 300Irbesartan
300 mg TabletAluminum Foil (Silver) - PVC/PVDC (Amber Brown) Blister Pack 3 x 10's (Box of 30's)
RxVAT-exempt
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY44329
Mar 16, 2030
Irbezet 150Irbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 35's); Alu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Roymed PharmaceuticalImporter: Nelpa Lifesciences, Inc.
DRP-17706-01
Feb 20, 2031
IrbezilIrbesartan
150 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Aurochem Pharmaceutical (I) Pvt. Ltd.India
Endure Medical, Inc.
DR-XY43308
Mar 24, 2029
IrbezilIrbesartan
300 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 100's
RxVAT-exempt
Aurochem Pharmaceutical (India) Pvt., Ltd.India
Endure Medical, Inc.
DR-XY43399
Nov 26, 2029
Irbezil 150Irbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Cooper Pharma LimitedIndia
Endure Medical, Inc.Importer: Ambica International Corporation
DRP-13010-03
Nov 17, 2027
Irbezil 300Irbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Cooper Pharma LimitedIndia
Endure Medical, Inc.Importer: Ambica International Corporation
DRP-13009-03
Nov 17, 2027
Irbezyd 150Irbesartan
150 mg Film-Coated TabletWhite Opaque PVC/PVDC/Alu Blister Pack x 10's (Box of 100's); White Opaque PVC/PVDC/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-9968
Jun 20, 2027
Irbezyd 300Irbesartan
300 mg Film-Coated TabletWhite Opaque PVC/PVDC/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-9999
Jun 20, 2032
Irbezyd 75Irbesartan
75 mg Film-Coated TabletWhite Opaque PVC/ PVDC/Alu Blister Pack x 10's (Box of 100's); (Box of 10's as Physician sample)
RxVAT-exempt
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-8027
Jun 20, 2027
IrbinIrbesartan
150 mg Film-Coated TabletAlu/White Opaque PDVC Blister Pack x 10's (Box of 30')
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc.
DRP-7554
Sep 15, 2029
IrbinIrbesartan
300 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Innogen Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc.
DRP-7555
Sep 15, 2029
Irbis H 150Irbesartan
150mg TabletWhite Opaque Alu/PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V and Unit V-A)India
Camber Pharmaceuticals, Inc.
DRP-11211
Feb 16, 2027
Irbis H 300Irbesartan
300mg TabletWhite Opaque Alu/PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V and Unit V-A)India
Camber Pharmaceuticals, Inc.
DRP-11212
Feb 16, 2027
Irbis H 75Irbesartan
75mg TabletWhite Opaque Alu/PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V and Unit V-A)India
Camber Pharmaceuticals, Inc.
DRP-11210
Feb 16, 2027
IRBOVELIRBESARTAN
150mg FIlm-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mepro Pharmaceuticals Private LimitedIndia
Medethix, Inc.
DRP-16216
Dec 17, 2031
IrbovelIrbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mepro Pharmaceuticals Private LimitedIndia
Medethix, Inc.
DRP-16215
Dec 17, 2031
Irebevex 150Irbesartan
150 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
West Coast Pharmaceutical Works. LtdIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DRP-7021
Sep 17, 2029
Irebevex 300Irbesartan
300 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
West Coast Pharmaceutical Works. LtdIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DRP-7022
Sep 17, 2029
IrtazepIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13010
Nov 17, 2027
IrtazepIrbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13009
Nov 17, 2027
IrvexIrbesartan
150 mg TabletFoil Strip x 4's (Box of 28's and 100’s); Foil Strip x 4's (Box of 8's as Physician's Sample); Foil Strip x 2's (Box of 2's and 8's as Physician's Sample)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
—
DRP-3839
May 16, 2031
IrvexIrbesartan
300 mg TabletFoil Strip x 4's (Box of 28's and 100's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
—
DRP-3871
May 16, 2031
MalatanIrbesartan
150 mg Film-Coated TabletWhite PVC/PVDC/Alu Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Genepharm SAGreece
S.M.H.P. Marketing & Consultancy
DRP-16784
Jul 11, 2030
MalatanIrbesartan
300 mg Film-Coated TabletWhite PVC/PVDC/Alu Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Genepharm SAGreece
S.M.H.P. Marketing & Consultancy
DRP-16785
Jul 11, 2030
Nobezart 300Irbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s)
RxVAT-exempt
Ratnaris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.Trader: N/A
DRP-18852
Sep 16, 2031
NoneIrbesartan
150 mg Film-Coated TabletAlu-White PVDC Blister Pack x 10's Box of 30's and 50's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Foramen Products Corporation
DR-XY40247
Oct 28, 2029
NoneIrbesartan
150 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DR-XY43587
Aug 5, 2029
NoneIrbesartan
150 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Reta DrugImporter: Teramedix Pharma Trading Inc.
DRP-13896-01
May 12, 2028
NoneIrbesartan
150 mg Film-Coated TabletAlu-White PVDC Blister Pack x 10's (Box of 30's and 50's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Foramen Products Corporation
DRP-17027
Oct 28, 2029
NoneIrbesartan
150 mg Film-Coated TabletAlu / White Opaque PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-17443
Aug 5, 2029
NoneIrbesartan
150 mg Film-Coated TabletAlu / White Opaque PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceuticals, Inc.
DRP-17443-01
Aug 5, 2029
NoneIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's and 7's (Box of 10's and 28's)
RxVAT-exempt
Lek Pharmaceuticals d.d.Slovenia
WATSONS PERSONAL CARE STORES (PHILIPPINES), INC.Importer: Sandoz Philippines Corporation
DRP-4386-01
Apr 26, 2028
NoneIrbesartan
150 mg Film-coated TabletAlu/White Opaque PVC/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Sanofi Winthrop IndustrieFrance
Sanofi Pasteur Inc.Importer: Sanofi-Aventis Philippines Inc.
DRP-5716-01
May 3, 2027
NoneIrbesartan
150 mg Film-Coated TabletAlu/White Opaque PVC/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Jubilant Generics LimitedIndia
Ritemed Phils., Inc.
DRP-5977
Jan 28, 2027
NoneIrbesartan
150 mg Film-Coated TabletWhite Opaque PVC/PVDC/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Cadila Healthcare LimitedIndia
Metro Drug, Inc.Importer: Zydus Healthcare Philippines, Inc.
DRP-9968-01
Jun 20, 2027
NoneIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-13010-01
Nov 17, 2027
NoneIrbesartan
150 mg TabletFoil Strip x 4's (Box of 100's); Foil Strip x 4's (Box of 8's as Physician Sample); Foil Strip x 2's (Box of 2's as Physician Sample)
RxVAT-exempt
Interphil Laboratories, Inc.Laguna
Icon Healthcare, Inc.
DRP-3839-01
May 16, 2031
NoneIrbesartan
150 mg TabletFoil Strip x 4's (Box of 100's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
St. Joseph Drugstore
DRP-3839-05
May 16, 2031
NoneIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines) Inc.Importer: Ambica International Corporation
DRP-6398-01
Oct 28, 2029
NoneIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-6398-02
Oct 28, 2029
NoneIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-6398-04
Oct 28, 2029
NoneIrbesartan
300 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DR-XY43811
Oct 27, 2029
NoneIrbesartan
300 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-15734
Sep 2, 2029
NoneIrbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Innovative HealthcareIndia
Actimed, IncImporter: Biophil Medical Equipment and Supplies Trading
DRP-17519-01
Jan 16, 2031
NoneIrbesartan
300 mg Film-Coated TabletAlu/White Opaque PVC/PVDC blister pack x 14's (Box of 28's)
RxVAT-exempt
Sanofi Winthrop Industrie-Carbon BlancFrance
Sanofi-Aventis Philippines, Inc.
DRP-5715-03
May 3, 2027
NoneIrbesartan
300 mg Film-Coated TabletAlu/White Opaque PVC/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Jubilant Generics LimitedIndia
Ritemed Phils., Inc.
DRP-5967
Jan 28, 2027
NoneIrbesartan
300 mg Film-Coated TabletWhite Opaque PVC/PVDC/Alu Blister Pack x 10's (Box of 100's); White Opaque PVC/PVDC/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cadila Healthcare LimitedIndia
Metro Drug Inc.Importer: Zydus Healthcare Philippines Inc.
DRP-9999-01
Jun 20, 2027
NoneIrbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-13009-01
Nov 17, 2027
NoneIrbesartan
300 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-13009-04
Nov 17, 2027
NoneIrbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-6399-01
Oct 28, 2029
NoneIrbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-6399-03
Oct 28, 2029
RibedimIrbesartan
150 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
DIAFARM INC.Importer: Ambica International Corporation
DRP-6398-03
Oct 28, 2029
Ribedim-300Irbesartan
300 mg TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
DIAFARM INC.Importer: Ambica International Corporation
DRP-6399-02
Oct 28, 2029
Saphbez-GE150Irbesartan
150 mg Film-Coated Tablet
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17706
Feb 20, 2031
Saphbez-GE300Irbesartan
300 mg Film-Coated Tablet
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17705
Feb 20, 2031
SarbetIrbesartan
300 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-12810
May 22, 2030
UnbrandedIrbesartan
150 mg Film-Coated TabletAlu/White Opaque PVdC Blister Pack x 10's Box of 30's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Actimed, Inc.Trader: Dr. Zen’s Research, Inc.
DRP-7554-02
Sep 15, 2029
UnbrandedIrbesartan
150 mg TabletFoil Strip x 4's (Box of 28's and 100's)
RxVAT-exempt
Interphil Laboratories, Inc.Laguna
Rose Pharmacy, Incorporated
DRP-3839-03
May 16, 2031
VirbezIrbesartan
150 mg TabletAlu-PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The ACME Laboratories LimitedBangladesh
Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc.
DRP-5686
Aug 6, 2028
Virbez 300Irbesartan
300 mg Film-Coated TabletOpaque white PVC/PVDC - Alu Blister Pack x 14's Box of 28's
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
BELL-KENZ PHARMA, INC.Importer: One Dexcel Pharma Inc.
DRP-8516
Oct 24, 2029
XartanovIrbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18871
Sep 16, 2031
(no brand name)Irbesartan
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mepro Pharmaceuticals Private LimitedIndia
MedEthix, Inc.
DRP-16603
May 15, 2030
(no brand name)Irbesartan
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mepro Pharmaceuticals Private LimitedIndia
MedEthix Inc.
DRP-18522
Jul 27, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS AVAPRO 150 mg is a white to off-white, biconvex oval, film-coated tablet debossed with a heart on one side and "2872" on the other. AVAPRO 300 mg is a white to off-white, biconvex oval, film-coated tablet debossed with a heart on one side and "2873" on the other. Tablets: 150 mg, 300 mg (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Hypotension: Correct volume or salt depletion prior to administration. (5.2)
  • Monitor renal function and serum potassium. (5.3)
5.1 Fetal Toxicity

5.1 Fetal Toxicity AVAPRO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.

Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue AVAPRO as soon as possible [see Use in Specific Populations (8.1)].

5.2 Hypotension in Volume or Salt-Depleted Patients

5.2 Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. Correct volume or salt depletion prior to administration of AVAPRO or use a lower starting dose [see Dosage and Administration (2.4)].

5.3 Impaired Renal Function

5.3 Impaired Renal Function Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion) may be at particular risk of developing acute renal failure or death on AVAPRO.

Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on AVAPRO [see Drug Interactions (7.3)].

Drug interactions

Drug interactions (US label) US FDA label

Lithium: Risk of lithium toxicity. (7) Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 inhibitors: Increased risk of renal impairment. Reduced antihypertensive effects. (7) Dual blockade of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. (7)

7.1 Agents Increasing Serum Potassium Coadministration

7.1 Agents Increasing Serum Potassium Coadministration of AVAPRO with other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. Monitor serum potassium in such patients.

7.2 Lithium

7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of irbesartan and lithium. Monitor lithium levels in patients receiving irbesartan and lithium.

7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2…

7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including irbesartan) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.

Monitor renal function periodically in patients receiving irbesartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.

7.4 Dual Blockade of the Renin-Angiotensin System (RAS)

7.4 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on AVAPRO and other agents that affect the RAS. Do not coadminister aliskiren with AVAPRO in patients with diabetes. Avoid use of aliskiren with AVAPRO in patients with renal impairment (GFR <60 mL/min).

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies indicate irbesartan is oxidized primarily by CYP2C9; metabolism by CYP3A4 is negligible.

Drug-Drug Interactions In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following important adverse reactions are described elsewhere in the labeling: Hypotension in Volume or Salt-Depleted Patients [see Warnings and Precautions (5.2)] Impaired Renal Function [see Warnings and Precautions (5.3)] Nephropathy in type 2 diabetic patients: The most common adverse reactions which were more frequent than placebo were hyperkalemia dizziness, orthostatic dizziness, and orthostatic hypotension. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Hypertension AVAPRO has been evaluated for safety in more than 4300 patients with hypertension and about 5000 subjects overall. This experience includes 1303 patients treated for over 6 months and 407 patients for 1 year or more. In placebo-controlled clinical trials, the following adverse reactions were reported in at least 1% of patients treated with AVAPRO (n=1965) and at a higher incidence versus placebo (n=641), excluding those too general to be informative and those not reasonably associated with the use of drug because they were associated with the condition being treated or are very common in the treated population, include: diarrhea (3% vs 2%), dyspepsia/heartburn (2% vs 1%), and fatigue (4% vs 3%).

Irbesartan use was not associated with an increased incidence of dry cough, as is typically associated with ACE inhibitor use. In placebo-controlled studies, the incidence of cough in irbesartan-treated patients was 2.8% versus 2.7% in patients receiving placebo. Nephropathy in Type 2 Diabetic Patients Hyperkalemia: In the Irbesartan Diabetic Nephropathy Trial (IDNT) (proteinuria ≥900 mg/day, and serum creatinine ranging from 1.0–3.0 mg/dL), the percent of patients with potassium >6 mEq/L was 18.6% in the AVAPRO group versus 6.0% in the placebo group.

Discontinuations due to hyperkalemia in the AVAPRO group were 2.1% versus 0.4% in the placebo group. In IDNT, the adverse reactions were similar to those seen in patients with hypertension with the exception of an increased incidence of orthostatic symptoms which occurred more frequently in the AVAPRO versus placebo group: dizziness (10.2% vs 6.0%), orthostatic dizziness (5.4% vs 2.7%) and orthostatic hypotension (5.4% vs 3.2%).

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of AVAPRO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.

Blood and lymphatic system: Anemia, Thrombocytopenia Ear and labyrinth: Tinnitus Gastrointestinal: Intestinal angioedema Hepatobiliary: Hepatitis, Jaundice Immune system: Anaphylactic reaction including anaphylactic shock Investigations: Increased liver function tests, Increased CPK (Creatine Phosphokinase) Metabolism and nutrition: Hyperkalemia, Hypoglycemia in diabetic patients Skin and subcutaneous tissue: Urticaria, Angioedema (involving swelling of the face, lips, pharynx, and/or tongue)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary AVAPRO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death [see Clinical Considerations]. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.

When pregnancy is detected, discontinue AVAPRO as soon as possible. All pregnancies have a background risk of birth defect, loss or other adverse outcomes regardless of drug exposure. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations Disease-associated maternal and/or embryo-fetal risk Hypertension in pregnancy increases the maternal risk for preeclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and postpartum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.

Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/neonatal adverse reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy.

Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. If oligohydramnios is observed, consider alternative treatment. Closely observe infants with histories of in utero exposure to AVAPRO for hypotension, oliguria, and hyperkalemia and other symptoms of renal impairment.

In neonates with a history of in utero exposure to AVAPRO, if oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. Data Animal data Irbesartan crosses the placenta in rats and rabbits.

In female rats given irbesartan prior to mating through gestation and lactation at oral doses of 50, 180, or 650 mg/kg/day (1.6 to 21.1 times the maximum recommended human dose (MRHD) based on body surface area), fetuses examined on Gestation Day 20 showed increased incidences of hydroureter and renal pelvic cavitation and/or absence of renal papilla in all irbesartan-treated groups. Subcutaneous edema also occurred in fetuses at maternal doses ≥180 mg/kg/day (5.8 times the MRHD).

These anomalies occurred when female rats received irbesartan from prior to mating through Day 20 of gestation but were not observed in pups postnatally in the same study, or when irbesartan was given to pregnant rats only during organogenesis (Gestation Day 6 through Gestation Day 15) at oral doses from 50 to 450 mg/kg/day (up to 14.6 times the MRHD). In addition, no adverse effects on kidney development were observed in pups from dams given irbesartan from Gestation Day 15 through Lactation Day 24 at doses of 50, 180, or 650 mg/kg/day (up to 21.1 times the MRHD).

The observed effects are believed to be late gestational effects of the drug. Pregnant rabbits given oral doses of irbesartan of 30 mg/kg/day (1.9 times the MRHD based on body surface area) experienced a high rate of maternal mortality and abortion. Surviving females had a slight increase in early resorptions and a corresponding decrease in live fetuses.

Radioactivity was present in the rat and rabbit fetuses during late gestation following oral doses of radiolabeled irbesartan.

Mechanism of action

12.1 Mechanism of Action Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex.

Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT 1 angiotensin II receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT 2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT 1 receptors with a much greater affinity (more than 8500-fold) for the AT 1 receptor than for the AT 2 receptor and no agonist activity.

Blockade of the AT 1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure. Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions. Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively).

In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5-fold to 2-fold rise in angiotensin II plasma concentration and a 2-fold to 3-fold increase in plasma renin levels. Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.

In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow, or filtration fraction. In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol or HDL-cholesterol concentrations.

There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Irbesartan is excreted in the milk of lactating rats.

Elimination Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively.

The terminal elimination half-life of irbesartan averages 11 to 15 hours.

Excretion Irbesartan and its metabolites are excreted by both biliary and renal routes.

In studies of hypertensive patients, there is no sex difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan are observed in females (11%–44%).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%. Following oral administration of AVAPRO, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing. Food does not affect the bioavailability of irbesartan.

Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range. Distribution Irbesartan is 90% bound to serum proteins (primarily albumin and α 1 -acid glycoprotein) with negligible binding to cellular components of blood. The average volume of distribution is 53 to 93 liters. Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.

Irbesartan is excreted in the milk of lactating rats. Elimination Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively. The terminal elimination half-life of irbesartan averages 11 to 15 hours. Steady-state concentrations are achieved within 3 days. Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing and is not clinically relevant.

Metabolism Irbesartan is an orally active agent that does not require biotransformation into an active form. Irbesartan is metabolized via glucuronide conjugation and oxidation. Following oral or intravenous administration of 14 C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.

The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%). The remaining oxidative metabolites do not add appreciably to irbesartan's pharmacologic activity. In vitro studies indicate irbesartan is oxidized primarily by CYP2C9; metabolism by CYP3A4 is negligible. Excretion Irbesartan and its metabolites are excreted by both biliary and renal routes.

Following either oral or intravenous administration of 14 C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide. Specific Populations Sex No sex-related differences in pharmacokinetics are observed in healthy elderly (age 65–80 years) or in healthy young (age 18–40 years) subjects.

In studies of hypertensive patients, there is no sex difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan are observed in females (11%–44%). No sex-related dosage adjustment is necessary. Geriatrics In elderly subjects (age 65–80 years), irbesartan elimination half-life is not significantly altered, but AUC and C max values are about 20% to 50% greater than those of young subjects (age 18–40 years).

No dosage adjustment is necessary in the elderly. Race/ethnicity In healthy black subjects, irbesartan AUC values are approximately 25% greater than whites; there is no difference in C max values. Renal impairment The pharmacokinetics of irbesartan is not altered in patients with renal impairment or in patients on hemodialysis.

Irbesartan is not removed by hemodialysis. No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted [see Warnings and Precautions (5.2) and Dosage and Administration (2.4)]. Hepatic insufficiency The pharmacokinetics of irbesartan following repeated oral administration are not significantly affected in patients with mild to moderate cirrhosis of the liver.

No dosage adjustment is necessary in patients with hepatic insufficiency. Drug-Drug Interactions In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine. However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.

Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4. In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days has no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.

The pharmacokinetics of irbesartan are not affected by coadministration of nifedipine or hydrochlorothiazide.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Irbesartan 150 mg Tablet₱2.24–₱3.77Reference ₱3.12per tabletDPRI procurement range
Irbesartan 300 mg Tablet₱6.51–₱14.99Reference ₱7.98per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Irbesartan
PNF listingOral: 150 mg and 300 mg tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Avapro · Sanofi-Aventis U.S. LLC [US FDA-approved label, version 22, August 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .